UK Markets closed

Oxford BioMedica plc (OXB.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
1,430.00-110.00 (-7.14%)
At close: 5:05PM BST
Full screen
Loading interactive chart…
  • Simply Wall St.

    Did You Miss Oxford Biomedica's (LON:OXB) Whopping 546% Share Price Gain?

    Long term investing can be life changing when you buy and hold the truly great businesses. And we've seen some truly...

  • Globe Newswire

    Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director

    Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director Oxford, UK – 15 July, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that Dr. Michael Hayden has been appointed to the Group’s Board as a Non-Executive Director, effective today. Dr. Hayden was the President of Global R&D and Chief Scientific Officer at Teva Pharmaceuticals Industries Ltd. from 2012 to 2017 during which time approximately

  • The Telegraph

    Oxford Biomedica to double AstraZeneca vaccine production

    Oxford Biomedica is doubling the volume of Covid vaccine it is making for AstraZeneca on the back of soaring demand for the jab. The biotech is one of two companies in the UK that manufactures the jab for AstraZeneca and is the pharmaceutical giant's biggest domestic supplier. John Dawson, chief executive of Oxford Biomedica, said production volumes would double by the end of the year to meet increased demand after the two companies revised their supply agreement. AstraZeneca would not confirm if the additional doses were being made for the domestic market or exported. The company said the extra supply was due to higher demand rather than manufacturing constraints elsewhere. The increase is a boon for Oxford Biomedica, which will see its vaccine sales rise from £50m to £100m by the end of the year and significantly boost profits. The news sent shares in the company up by more than 13pc.